Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
Hypovase 1 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. White oblong tablets scored on both sides and engraved “M6” on one side. The tablet can be divided into equal doses. |
Prazosin hydrochloride equivalent to 1 mg prazosin based on a potency of 93.1 % base activity.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Prazosin |
Prazosin causes a decrease in total peripheral vascular resistance through selective inhibition of postsynaptic alpha-1-adrenoreceptors in vascular smooth muscle. Prazosin has been found to successfully reduce the severity of the signs, symptoms, frequency and duration of attacks, in patients with Raynaud’s disease. |
| List of Excipients |
|---|
|
Calcium phosphate dibasic anhydrous |
PVC/Aluminium blisters in cartons of 60 tablets (blister strips of 4 × 15 tablets).
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
PL 00057/0106R
Date of first authorisation: 19 October 1988
Date of last renewal: 22 November 2004
| Drug | Countries | |
|---|---|---|
| HYPOVASE | Ireland, Malta, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
